Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT06075524
Official study title

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

Study summary

This study explores the role of T cells in monitoring disease status and response during anti-PD-1/PD-L1 treatment in patients with melanoma, lung and other cancer types. Measuring levels of specific targets such as Bim and soluble PD-L1 during therapy may help track treatment resistance and clinical outcomes. This information may also help researchers determine why some people with melanoma, lung and other cancer types respond to PD-1/PD-L1 treatment and others do not.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedBiospecimen Collection and Electronic Health Record Review

The study team can explain what participation involves.

Who it may be forPD-L1 · Locally advanced · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 18, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Mayo Clinic

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Mayo Clinic
Interventions being studied
Procedure: Biospecimen Collection; Other: Electronic Health Record Review
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Locally advanced→Metastatic or stage IV→
Biomarkers
PD-L1→
Treatment approach
Immunotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Are 18 years of age or older
  • Have histologic evidence of locally or regionally advanced or stage IV malignancy
  • Are considered appropriate for starting therapy with anti-PD-1/anti-PD-L1 monoclonal antibody by their treating physician (prior therapy with immune checkpoint inhibitor (ICI) is allowed)
  • Have an understanding of the protocol and its requirements, risks, and discomforts
  • Are willing to undergo peripheral blood collection at the time points mentioned in the protocol
  • Are able and willing to sign an informed consent
Reasons someone may not be able to joinExclusion criteria
  • Inability on the part of the patient to understand the informed consent or be compliant with the protocol
  • Patients receiving any concurrent anti-cancer therapy or investigational agents (with the exception of an anti-PD-1/anti-PD-L1 agent as mentioned above)
  • Patients who are pregnant, nursing, or are of childbearing potential and are unwilling to employ adequate contraception

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Mayo Clinic in RochesterRochester, Minnesota

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 18, 2026. Always confirm current availability with the study team.

View original record ↗